

Optimal therapy of chronic obstructive pulmonary disease to prevent exacerbations and improve quality of life

Submission date 17/06/2005	Recruitment status No longer recruiting	☐ Prospectively registered ☐ Protocol
Registration date 17/06/2005	Overall study status Completed	☐ Statistical analysis plan ☒ Results
Last Edited 25/02/2009	Condition category Respiratory	☐ Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Shawn David Aaron

Contact details
The Ottawa Hospital
Division of Respiratory Medicine
501 Smyth Road, Room 1812F
Ottawa, Ontario
Canada
K1H 8L6
+1 613 739 6636
saaron@ohri.ca

Additional identifiers

Protocol serial number
MCT-63139

Study information

Scientific Title

Optimal therapy of chronic obstructive pulmonary disease to prevent exacerbations and improve quality of life: a randomised, double-blind, placebo-controlled trial

Study objectives

To determine what combination of inhaled medications will most effectively prevent exacerbations of chronic obstructive pulmonary disease (COPD) and optimise disease-specific quality of life in patients with COPD.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Ottawa Hospital Research Ethics Board approval was obtained on the 9th April 2003 (amendments: November 4, 2003; January 29, 2004; June 22, 2004).

Primary study design

Interventional

Study design

Randomised, double-blind, placebo-controlled trial

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Chronic obstructive pulmonary disease (COPD)

Interventions

1. Tiotropium 18 µg once a day (OD) plus advair 250 µg two puffs twice a day (BID)
2. Tiotropium 18 µg OD plus salmeterol 25 µg/puffs, two puffs BID
3. Tiotropium 18 µg OD plus placebo inhaler, two puffs BID

Pro re nata (PRN) (as needed) salbutamol use will be allowed throughout the trial period.

Intervention Type

Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Tiotropium, advair, salmeterol

Primary outcome(s)

Proportion of patients who experience a respiratory exacerbation in the three treatment groups within 52 weeks of randomisation.

Key secondary outcome(s)

1. Changes in quality of life using Chronic Respiratory Disease Questionnaire (CRDQ) and St George's Respiratory Questionnaire (SGRQ) scores
2. Changes in dyspnoea using the baseline Transitional Dyspnoea Indexes (TDI) and Chronic

Respiratory Questionnaire (CRQ) dyspnoea domain

3. Number of exacerbations resulting in urgent visits to healthcare provider; or emergency department visits

4. Total number of hospitalisations (all causes)

5. Time to first COPD exacerbation

6. Mean/median number of exacerbations in each treatment group

7. Absolute and relative changes in the morning pre-treatment FEV1 and FVC

8. Use of as-needed salbutamol (puffs/day) - as assessed by patients diary

9. Premature discontinuation of study medication, for reasons of diverse effects or lack of efficacy, as judged by patients physician

Completion date

05/01/2006

Eligibility

Key inclusion criteria

1. Patients with moderate or severe COPD who have had at least one exacerbation of COPD in the last 12 months requiring antibiotics and/or oral steroids

2. Patients 35 years and older, either sex

3. Patients must have a history of at least 10-pack years of smoking, and documented chronic airflow obstruction with a forced expiratory volume in one second (FEV1)/forced vital capacity (FVC) ratio of less than 0.70, and an FEV1 of less than 65% of predicted

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

All

Key exclusion criteria

1. Patients with a history of atopy, or asthma diagnosed before age 40

2. Patients less than 35 years of age (since patients younger than 35 are unlikely to have COPD)

3. Patients using chronic oral prednisone

4. Patients with known hypersensitivity or intolerance to tiotropium, advair, or salmeterol

5. Patients with a history of chronic congestive heart failure and known severe left ventricular dysfunction (which can mimic and be confused with COPD exacerbation)

6. Patients unable to provide informed consent due to language difficulties or cognitive impairment

Date of first enrolment

08/10/2003

Date of final enrolment

05/01/2006

Locations

Countries of recruitment

Canada

Study participating centre

The Ottawa Hospital

Ottawa, Ontario

Canada

K1H 8L6

Sponsor information

Organisation

Ottawa Hospital Research Institute (Canada)

ROR

<https://ror.org/03c62dg59>

Funder(s)

Funder type

Research organisation

Funder Name

Canadian Institutes of Health Research (CIHR) (Canada) - <http://www.cihr-irsc.gc.ca> (ref: MCT-63139)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
-------------	---------	--------------	------------	----------------	-----------------

[Results article](#)

results

17/04/2007

Yes

No